Efficacy of Lubiprostone in Combination With Standard PEG Preparation
Takeda Pharmaceuticals North America, Inc.
A large population-based study has shown diabetes to be an independent risk factor for colon
cancer compared to the general population. Thus, the completion of an adequately prepped
colonoscopy is requisite in providing diabetics with adequate colon cancer screening.
Recent data has shown that diabetic patients have poorer response to bowel cleansing
compared to non-diabetics (with a standard PEG prep, only 62% of diabetic patients had their
colonoscopy preps rated as good or better vs. 97% of normal patients, p<0.001). This may be
due to the fact that a majority of diabetic patients report constipation as a common
We postulate that lubiprostone (Amitiza), in combination with PEG, will have additional
efficacy over standard PEG preparation, and provide optimal safe and effective colonic
cleansing for diabetics.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.